Menu Search
Equities

Cellectar Biosciences Inc

NV4:FRA

Cellectar Biosciences Inc

Actions
  • Price (EUR)2.96
  • Today's Change0.02 / 0.68%
  • Shares traded-1.00
  • 1 Year change+104.14%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024 07:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

  • Revenue in USD (TTM)0.00
  • Net income in USD-50.98m
  • Incorporated1996
  • Employees20.00
  • Location
    Cellectar Biosciences Inc100 Campus DriveFLORHAM PARK 07932United StatesUSA
  • Phone+1 (608) 441-8120
  • Fax+1 (608) 441-8121
  • Websitehttps://www.cellectar.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.